Mirati, Aadi Partner to Evaluate Therapies for Lung Cancer and Other Solid Tumors

  Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, and Aadi Bioscience, Inc (Nasdaq: AADI), a commercial stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced a clinical collaboration to evaluate the combination of adagrasib, a KRAS^G12C selective inhibitor, and nab-sirolimus, a small molecule mTOR inhibitor complexed with human albumin in KRAS ^G12C mutant non-small cell lung cancer (NSCLC) and other solid tumors.

The primary objective of this multi-center, single-arm, open-label Phase 1/2 trial is to determine the optimal dose and recommended Phase 2 dose for the combination of adagrasib and nab-sirolimus in patients with KRAS^G12C - mutant solid tumors. In addition, the study will investigate the safety, tolerability and efficacy of adagrasib and nab-sirolimus in combination in patients both with and without prior exposure to a KRAS^G12C inhibitor. The trial will build on preclinical data showing enhanced anti-tumor efficacy with the combination of adagrasib and nab-sirolimus relative to either agent alone.

https://www.biospace.com/article/releases/mirati-therapeutics-and-aadi-bioscience-partner-to-evaluate-the-combination-of-adagrasib-with-nab-sirolimus-in-patients-with-advanced-non-small-cell-lung-cancer-and-other-solid-tumors-with-a-kras-g12c-mutation/